Apellis Pharmaceuticals Inc at Citi BioPharma Conference Transcript
Welcome, everyone. I'm Yigal Nochomovitz. I'm one of the biotech analysts at Citi. I cover Apellis since the IPO many years ago. So it's my pleasure to have with me Cedric Francois, the Co-Founder, President and CEO; David Acheson, who is SVP of North America Commercial; and the CFO of Apellis, Tim Sullivan. So welcome, gentlemen. Thank you so much. It's great to have you here. It's amazing. It's been a year since we did this last fall.
Questions & Answers
So let's start with some of the obvious debates. Maybe just as a first step, could you just give us an update on what you're seeing with the vasculitis events? How is that evolving? Is the rate the same? Is there anything new to say there relative to the last update you had a press release a few weeks ago, I think the end of August with some more data and the cadence of how often you'll continue to update the market on that important issue?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
